| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $257,688 | 1 | 6 |
Sells | $146,533,480 | 17 | 94 |
| MORIKIS JOHN G | director | 1 | $257,688 | 0 | $0 | $257,688 |
| Decker Robert J | VP Corporate Controller | 0 | $0 | 1 | $1.01M | $-1.01M |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | 0 | $0 | 1 | $2.41M | $-2.41M |
| Forminard Elizabeth | EVP, Chief Legal Officer | 0 | $0 | 1 | $4.09M | $-4.09M |
| Broadhurst Vanessa | EVP, Global Corp Affairs | 0 | $0 | 2 | $7.3M | $-7.3M |
| REED JOHN C | EVP, Innovative Medicine, R&D | 0 | $0 | 2 | $12.01M | $-12.01M |
| Schmid Timothy | EVP, WW Chair, MedTech | 0 | $0 | 3 | $12.04M | $-12.04M |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 0 | $0 | 2 | $13.99M | $-13.99M |
| Swanson James D. | EVP, CIO | 0 | $0 | 2 | $15.11M | $-15.11M |
| Wolk Joseph J | Exec VP, CFO | 0 | $0 | 1 | $21.77M | $-21.77M |
| Duato Joaquin | CEO and Chairman of the Board | 0 | $0 | 3 | $66.84M | $-66.84M |
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Over the last 12 months, insiders at Johnson & Johnson have bought $257,688 and sold $146.53M worth of Johnson & Johnson stock.
On average, over the past 5 years, insiders at Johnson & Johnson have bought $202,454 and sold $64.81M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MORIKIS JOHN G (director) — $257,688.
The last purchase of 1,250 shares for transaction amount of $257,688 was made by MORIKIS JOHN G (director) on 2025‑11‑26.
| 2026-09-02 | Sale | Schmid Timothy | EVP, WW Chair, MedTech | 22,527 0.0009% | $274.74 | $6.19M | +0.18% | |
| 2026-08-17 | Sale | Taubert Jennifer L | EVP, WWC. Innovative Medicine | 15,000 0.0006% | $263.36 | $3.95M | +3.35% | |
| 2026-08-13 | Sale | Duato Joaquin | CEO and Chairman of the Board | 123,291 0.0051% | $261.17 | $32.2M | +3.28% | |
| 2026-08-06 | Sale | Forminard Elizabeth | EVP, Chief Legal Officer | 15,918 0.0007% | $257.00 | $4.09M | +4.30% | |
| 2026-08-05 | Sale | Duato Joaquin | CEO and Chairman of the Board | 48,480 0.002% | $258.15 | $12.52M | +3.93% | |
| 2026-07-20 | Sale | Broadhurst Vanessa | EVP, Global Corp Affairs | 23,054 0.001% | $251.27 | $5.79M | +6.22% | |
| 2026-06-11 | Sale | Wengel Kathryn E | EVP, Chief TO and Risk Officer | 10,000 0.0004% | $241.15 | $2.41M | +8.77% | |
| 2026-02-27 | Sale | Decker Robert J | VP Corporate Controller | 4,075 0.0002% | $247.87 | $1.01M | -2.78% | |
| 2026-02-20 | Sale | Schmid Timothy | EVP, WW Chair, MedTech | 1,322 <0.0001% | $245.66 | $324,763 | +0.46% | |
| 2026-02-18 | Sale | Schmid Timothy | EVP, WW Chair, MedTech | 22,623 0.0009% | $244.33 | $5.53M | -0.56% | |
| 2026-02-17 | Sale | Swanson James D. | EVP, CIO | 20,521 0.0008% | $242.70 | $4.98M | +0.14% | |
| 2026-02-17 | Sale | Broadhurst Vanessa | EVP, Global Corp Affairs | 6,197 0.0003% | $243.39 | $1.51M | +0.14% | |
| 2026-02-17 | Sale | Wolk Joseph J | Exec VP, CFO | 89,654 0.0037% | $242.80 | $21.77M | +0.14% | |
| 2026-02-17 | Sale | REED JOHN C | EVP, Innovative Medicine, R&D | 32,210 0.0013% | $243.00 | $7.83M | +0.14% | |
| 2026-02-13 | Sale | Swanson James D. | EVP, CIO | 41,559 0.0017% | $243.73 | $10.13M | +0.06% | |
| 2026-01-26 | Sale | Duato Joaquin | CEO and Chairman of the Board | 100,000 0.0041% | $221.23 | $22.12M | +9.52% | |
| 2025-11-26 | MORIKIS JOHN G | director | 1,250 <0.0001% | $206.15 | $257,688 | +15.26% | ||
| 2025-10-17 | Sale | REED JOHN C | EVP, Innovative Medicine, R&D | 21,721 0.0009% | $192.71 | $4.19M | +22.62% | |
| 2025-09-04 | Sale | Taubert Jennifer L | EVP, WWC. Innovative Medicine | 56,471 0.0023% | $177.81 | $10.04M | +30.09% | |
| 2025-08-22 | Sale | Duato Joaquin | CEO and Chairman of the Board | 125,824 0.0052% | $179.21 | $22.55M | +29.09% |
| Duato Joaquin | CEO and Chairman of the Board | 275967 0.0115% | $75.95M | 0 | 6 | |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 194451 0.0081% | $53.52M | 0 | 4 | |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | 114288 0.0047% | $31.46M | 0 | 6 | |
| Swanson James D. | EVP, CIO | 25698 0.0011% | $7.07M | 0 | 3 | |
| Schmid Timothy | EVP, WW Chair, MedTech | 25447 0.0011% | $7M | 0 | 4 | |
| Decker Robert J | VP Corporate Controller | 23682 0.001% | $6.52M | 0 | 7 | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | 23003 0.001% | $6.33M | 0 | 3 | |
| Forminard Elizabeth | EVP, Chief Legal Officer | 16994 0.0007% | $4.68M | 0 | 1 | |
| Wolk Joseph J | Exec VP, CFO | 14000 0.0006% | $3.85M | 0 | 4 | |
| REED JOHN C | EVP, Innovative Medicine, R&D | 10658 0.0004% | $2.93M | 0 | 3 | |
| MORIKIS JOHN G | director | 1849 0.0001% | $508,765.41 | 1 | 0 | |
| WILSON ROBERT N | Retired Director/Vice Chairman | 889154 0.0369% | $244.72M | 0 | 1 | |
| WELDON WILLIAM C | Former Chairman of the Board | 407364 0.0169% | $112.12M | 0 | 9 | |
| Gorsky Alex | Chairman, CEO | 336559 0.014% | $92.63M | 0 | 1 | |
| DARRETTA ROBERT J | Vice Chairman | 209118 0.0087% | $57.56M | 0 | 3 | |
| Stoffels Paulus | Exec VP, Chief Scientific Off | 202564 0.0084% | $55.75M | 0 | 6 | |
| LENEHAN JAMES T | Former Vice Chairman/Director | 199372 0.0083% | $54.87M | 0 | 1 | |
| FINE ROGER S | Retired Exec Committee Member | 191226 0.0079% | $52.63M | 0 | 1 | |
| HEISEN JOANN HEFFERNAN | VP, Chief Information Officer | 161864 0.0067% | $44.55M | 0 | 4 | |
| Caruso Dominic J | Exec VP, Finance; CFO | 144102 0.006% | $39.66M | 0 | 9 | |
| GOGGINS COLLEEN A | Member, Executive Committee | 105922 0.0044% | $29.15M | 0 | 9 | |
| Fasolo Peter | Exec VP, Chief HR Officer | 102696 0.0043% | $28.27M | 0 | 11 | |
| Ullmann Michael H | Exec VP, General Counsel | 97455 0.004% | $26.82M | 0 | 4 | |
| COSGROVE STEPHEN J | Corporate Controller | 90294 0.0037% | $24.85M | 0 | 13 | |
| Hait William | See Remarks | 87747 0.0036% | $24.15M | 0 | 3 | |
| PERKINS BRIAN D | Former Member Exec Committee | 61899 0.0026% | $17.04M | 0 | 3 | |
| Sneed Michael E | EVP, Global Corp Aff & COO | 56079 0.0023% | $15.43M | 0 | 4 | |
| VALERIANI NICHOLAS J | VP, Strategy & Growth, other: Member, Executive Committee | 53318 0.0022% | $14.67M | 0 | 6 | |
| McCoy Sherilyn S | Member, Executive Committee | 49243 0.002% | $13.55M | 0 | 3 | |
| Pruden Gary J | Exec VP, WW Chair, Med Devices | 43630 0.0018% | $12.01M | 0 | 2 | |
| McEvoy Ashley | EVP, WW Chair, MedTech | 41813 0.0017% | $11.51M | 0 | 2 | |
| Mongon Thibaut | Exec VP, WW Chair, Consumer | 40133 0.0017% | $11.05M | 0 | 3 | |
| PRINCE CHARLES | director | 28520 0.0012% | $7.85M | 6 | 0 | +5.16% |
| Casey Donald M Jr. | Member, Executive Committee | 22536 0.0009% | $6.2M | 0 | 1 | |
| DORMER MICHAEL J | Member, Executive Committee | 18499 0.0008% | $5.09M | 0 | 1 | |
| Scodari Joseph C | Retired Exec Committee Member | 18646 0.0008% | $5.13M | 0 | 2 | |
| PEREZ WILLIAM D | director | 16030 0.0007% | $4.41M | 14 | 0 | +2.64% |
| COLEMAN MARY SUE | director | 14352 0.0006% | $3.95M | 0 | 1 | |
| PETERSON PER A | Executive Committee Member | 14195 0.0006% | $3.91M | 0 | 6 | |
| LINDQUIST SUSAN L | director | 14605 0.0006% | $4.02M | 0 | 1 | |
| Kapusta Ronald A | Controller, CAO | 13641 0.0006% | $3.75M | 0 | 8 | |
| LANGBO ARNOLD G | director | 6367 0.0003% | $1.75M | 0 | 5 | |
| MULCAHY ANNE M | director | 6537 0.0003% | $1.8M | 1 | 0 | +1.81% |
| JORDAN ANN DIBBLE | director | 5933 0.0002% | $1.63M | 0 | 1 | |
| Foster-Cheek Kaye I | VP, Human Resources | 4583 0.0002% | $1.26M | 0 | 1 | |
| Joly Hubert | director | 5000 0.0002% | $1.38M | 1 | 0 | +5.24% |
| CULLEN JAMES | director | 1489 0.0001% | $409,817.47 | 0 | 12 | |
| DEYO RUSSELL C | VP, General Counsel | 2478 0.0001% | $682,019.94 | 0 | 21 | |
| SATCHER DAVID | director | 2491 0.0001% | $685,597.93 | 1 | 0 | +1.72% |
| HEWSON MARILLYN A | director | 3000 0.0001% | $825,690.00 | 1 | 0 | +0.23% |
| WEINBERGER MARK A | director | 1000 0% | $275,230.00 | 1 | 0 | +12.35% |
$1,927,310,793 | 31 | 28.02% | $1,081.31B | |
$364,368,632 | 29 | 9.65% | $32.63B | |
Johnson & Johnson (JNJ) | $6,224,380 | 25 | 3.57% | $663.28B |
$23,541,811 | 22 | 6.43% | $136.49B | |
$28,542,809 | 19 | 26.40% | $452.9B | |
$18,601,970 | 18 | 3.54% | $371.31B | |
$2,523,290 | 18 | -0.85% | $162.15B | |
$356,328 | 15 | -42.83% | $45.98M | |
$3,170,734 | 10 | 3.97% | $235.98B | |
$3,933,798 | 8 | 12.51% | $187.47B | |
$904,305 | 8 | 2.57% | $3.62B | |
$8,176 | 1 | 13.73% | $32.1M |
| Increased Positions | 2,187 | +46.82% | 82M | +4.66% |
| Decreased Positions | 2,121 | -45.41% | 67M | -3.8% |
| New Positions | 472 | New | 20M | New |
| Sold Out Positions | 117 | Sold Out | 5M | Sold Out |
| Total Postitions | 4,737 | +1.41% | 2B | +0.86% |
| Vanguard Group Inc | $49.06M | 9.82% | 236.62M | -429,273 | -0.18% | 2025-09-30 |
| Blackrock, Inc. | $42.98M | 8.6% | 207.26M | +3M | +1.67% | 2025-09-30 |
| State Street Corp | $27.41M | 5.49% | 132.21M | -591,274 | -0.45% | 2025-09-30 |
| Jpmorgan Chase & Co | $12.16M | 2.43% | 58.64M | +3M | +4.53% | 2025-09-30 |
| Geode Capital Management, Llc | $11.66M | 2.33% | 56.22M | -4M | -7.25% | 2025-09-30 |
| Morgan Stanley | $10M | 2% | 48.23M | +1M | +2.65% | 2025-09-30 |
| Norges Bank | $6.62M | 1.33% | 31.93M | +2M | +5.18% | 2025-06-30 |
| State Farm Mutual Automobile Insurance Co | $6.55M | 1.31% | 31.59M | -84,540 | -0.27% | 2025-09-30 |
| Northern Trust Corp | $6.21M | 1.24% | 29.97M | -360,490 | -1.19% | 2025-09-30 |
| Bank Of America Corp /De/ | $5.89M | 1.18% | 28.42M | +898,834 | +3.27% | 2025-09-30 |